Literature DB >> 25285729

Heterotopic auxiliary rat liver transplantation with flow-regulated portal vein arterialization in acute hepatic failure.

Karina Schleimer1, Johannes Kalder2, Jochen Grommes2, Houman Jalaie2, Samir Tawadros2, Andreas Greiner2, Michael Jacobs2, Maria Kokozidou2.   

Abstract

In acute hepatic failure auxiliary liver transplantation is an interesting alternative approach. The aim is to provide a temporary support until the failing native liver has regenerated.(1-3) The APOLT-method, the orthotopic implantation of auxiliary segments- averts most of the technical problems. However this method necessitates extensive resections of both the native liver and the graft.(4) In 1998, Erhard developed the heterotopic auxiliary liver transplantation (HALT) utilizing portal vein arterialization (PVA) (Figure 1). This technique showed promising initial clinical results.(5-6) We developed a HALT-technique with flow-regulated PVA in the rat to examine the influence of flow-regulated PVA on graft morphology and function (Figure 2). A liver graft reduced to 30 % of its original size, was heterotopically implanted in the right renal region of the recipient after explantation of the right kidney.  The infra-hepatic caval vein of the graft was anastomosed with the infrahepatic caval vein of the recipient. The arterialization of the donor's portal vein was carried out via the recipient's right renal artery with the stent technique. The blood-flow regulation of the arterialized portal vein was achieved with the use of a stent with an internal diameter of 0.3 mm. The celiac trunk of the graft was end-to-side anastomosed with the recipient's aorta and the bile duct was implanted into the duodenum. A subtotal resection of the native liver was performed to induce acute hepatic failure. (7) In this manner 112 transplantations were performed. The perioperative survival rate was 90% and the 6-week survival rate was 80%. Six weeks after operation, the native liver regenerated, showing an increase in weight from 2.3±0.8 g to 9.8±1 g. At this time, the graft's weight decreased from 3.3±0.8 g to 2.3±0.8 g. We were able to obtain promising long-term results in terms of graft morphology and function. HALT with flow-regulated PVA reliably bridges acute hepatic failure until the native liver regenerates.

Entities:  

Mesh:

Year:  2014        PMID: 25285729      PMCID: PMC4828065          DOI: 10.3791/51115

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

Review 1.  Fulminant hepatic failure.

Authors:  A Mas; J Rodés
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

2.  Portal hyperperfusion causes disturbance of microcirculation and increased rate of hepatocellular apoptosis: investigations in heterotopic rat liver transplantation with portal vein arterialization.

Authors:  K Schleimer; D L Stippel; H-U Kasper; S Tawadros; R Allwissner; C Gaudig; T Greiner; A H Hölscher; K T E Beckurts
Journal:  Transplant Proc       Date:  2006-04       Impact factor: 1.066

3.  Liver transplantation in the rat.

Authors:  S Lee; T S Edgington
Journal:  Surg Forum       Date:  1966

4.  Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure--a multicenter European study.

Authors:  M P Chenard-Neu; K Boudjema; J Bernuau; C Degott; J Belghiti; D Cherqui; V Costes; J Domergue; F Durand; J Erhard; B De Hemptinne; G Gubernatis; A Hadengue; J Kemnitz; M McCarthy; H Maschek; G Mentha; K Oldhafer; B Portmann; M Praet; J Ringers; X Rogiers; L Rubbia; S Schalm; J P Bellocq
Journal:  Hepatology       Date:  1996-05       Impact factor: 17.425

5.  Auxiliary partial orthotopic liver transplantation: treatment of acute liver failure in a new rat model.

Authors:  D Palmes; K H Dietl; G Drews; J P Hölzen; H Herbst; H U Spiegel
Journal:  Langenbecks Arch Surg       Date:  2001-11-30       Impact factor: 3.445

6.  Temporary auxiliary liver transplantation for subacute liver failure in a child.

Authors:  K Boudjema; D Jaeck; U Siméoni; J Bientz; M P Chenard; P Brunot
Journal:  Lancet       Date:  1993-09-25       Impact factor: 79.321

7.  Auxiliary liver transplantation with arterialization of the portal vein for acute hepatic failure.

Authors:  J Erhard; R Lange; U Rauen; R Scherer; J Friedrich; M Pietsch; H de Groot; F W Eigler
Journal:  Transpl Int       Date:  1998       Impact factor: 3.782

8.  Auxiliary partial orthotopic liver transplantation (APOLT) for fulminant hepatic failure: first successful case report.

Authors:  G Gubernatis; R Pichlmayr; J Kemnitz; K Gratz
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

9.  Study of portal arterialization with auxiliary liver in rats.

Authors:  H Q Hong; T Asahara; H Ito; H Watanabe; A Kimura; T Urushihara; S Marubayashi; Y Fukuda; M Nishiki; K Dohi
Journal:  Hiroshima J Med Sci       Date:  1991-03

10.  Auxiliary liver transplantation for fulminant and subfulminant hepatic failure.

Authors:  K Boudjema; D Cherqui; D Jaeck; M P Chenard-Neu; A Steib; G Freis; F Becmeur; B Brunot; U Simeoni; J P Bellocq
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

View more
  3 in total

1.  Surgical Models to Explore Acellular Liver Scaffold Transplantation: Step-by-Step.

Authors:  Marlon L Dias; Cíntia M P Batista; Victor J K Secomandi; Alexandre C Silva; Victoria R S Monteiro; Lanuza A Faccioli; Regina C S Goldenberg
Journal:  Organogenesis       Date:  2020-08-15       Impact factor: 2.500

2.  Chinese Herb Jiedu Huayu Granules Inhibiting Immune and Inflammatory Response of Rats with Acute Liver Failure by Regulating the NF-κB Signaling Pathway.

Authors:  Wenjie Bai; Qinglan Shi; Jinyu Wu; Kejing Wang; Yueqiao Chen; Xiaocong Ma; Dewen Mao
Journal:  Biomed Res Int       Date:  2022-05-11       Impact factor: 3.246

3.  Improved donor liver position selection and revascularization for heterotopic auxiliary liver transplantation with portal vein arterialization.

Authors:  Jun Li; Yujun Zhang; Jianjun Ren; Junjing Zhang; Jianliang Qiao; Xingkai Meng
Journal:  Int J Clin Exp Med       Date:  2015-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.